Deep-dive stock research and institutional-grade analysis.
Research
Oil above $100 is a fresh stress test for floating-rate borrowers, but the contrarian risk is margin compression and selective restructuring, not a systemic private-credit collapse.
Research
Lululemon's 81% slide looks cheap, but the harder question is whether the brand needs a multi-year reset before the old margin engine can return.
Research
The NFL is putting five games on Netflix, but the contrarian trade is scarcity: selective streaming can raise the value of every remaining rights window.
Research
The ECB's second hike of 2026 is a hedge against an energy shock, but softer core prices and modest growth forecasts make recession risk the cleaner contrarian trade.
Research
Apple's $1,999 iPhone Duo creates a premium growth tier, but the real test is pricing power and mix, not a mass-market foldable boom.
Research
Copper is making records, but the signal is policy-driven scarcity: metal is moving into US warehouses while global surplus risk remains unresolved.
Research
China's reserves beat expectations in August as the yuan rose and the dollar fell. The signal is managed appreciation and export protection, not a dollar exit.
Research
Novartis's failed Lp(a) trial did not break biotech's rebound. It exposed the market's real test: capital is returning, but only to clinical proof and de-risked assets.
Research
Kevin Warsh lifted September hike odds without offering a rate path. The contrarian trade is a credibility repair, not a policy promise.
Research
The NFL's three-way sportsbook reset looks like expansion. The real trade is tighter control of data, inventory and prediction-market boundaries.
Research
Health insurers are rebounding on better claims discipline, but the trade is pricing margin repair and selective shrinking, not a return to easy membership growth.
Research
U.S. diesel stocks hit a record seasonal low as refiners run near capacity. The contrarian risk is a persistent product shortage, not simply a crude spike.